New hope for egyptian women with aggressive breast cancer: targeted therapy works
NCT ID NCT07416409
First seen Feb 22, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This study followed 80 Egyptian women with HER2-positive breast cancer to see how well anti-HER2 drugs like trastuzumab work in real life. The goal was to measure survival and side effects. Researchers compared single-drug versus combination therapy to find the best approach for this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dar Al-Salam Cancer Hospital
Cairo, Menia Governorate, Egypt
Conditions
Explore the condition pages connected to this study.